Viridian Therapeutics, Inc. (VRDN)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 1 | 3 | 2 | 0 | 0 | 71 | 71 | 24 |
| Operating profit | $m | -363 | -405 | ||||||
| Net profit | $m | -111 | -79 | -130 | -238 | -270 | -343 | -387 | -340 |
| EPS reported | $ | -3.32 | -3.53 | ||||||
| Operating cashflow per share | $ | -3.26 | -3.09 | ||||||
| Capex per share | $ | 0.01 | 0.02 | ||||||
| FCF per share | $ | -3.27 | -3.11 | ||||||
| Free cash flow | $m | -277 | -335 | ||||||
| Net debt | $m | -825 | -739 | ||||||
| Book value equity | $m | 722 | 662 | ||||||
| Book value per share | $ | 8.52 | 6.14 | ||||||
| Number of shares | m | 84.8 | 107.88 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 3.65 | 3.99 | ||||||
| P/S LTM | x | 37.25 | 37.10 | ||||||
| P/FCF LTM | x | -9.53 | -7.88 | ||||||
| EV/EBITDA LTM | x | -7.35 | -6.73 | ||||||
| EV/Sales LTM | x | 34.97 | 30.23 | ||||||
| Earnings Yield LTM | % | -12.98% | -15.58% | ||||||
| FCF Yield | % | -10.49% | -12.70% | ||||||
| Quality | |||||||||
| ROE | % | -47.44% | -61.35% | ||||||
| ROIC | % | -43.81% | -39.21% | ||||||
| Operating margin | % | -5.13% | -5.70% | ||||||
| Gross margin | % | +100.00% | +99.38% | ||||||
| FCF/Sales | % | -390.81% | -471.04% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | - | - | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -5.46 | -1.38 | ||||||
| Net Debt/EBITDA | x | 0.48 | -0.21 | ||||||
| EBIT/Net interest | x | -73.44 | -21.40 | ||||||
| Net debt/market cap | % | +1.89% | +11.68% | ||||||
| Net debt/Equity | x | -1.14 | -1.12 | ||||||
| Gross debt/equity | x | 0.07 | 0.37 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Viridian Therapeutics, Inc. is a biotechnology firm committed to creating therapies for patients afflicted by serious illnesses. Its primary development efforts include VRDN-001, a humanized monoclonal anti-IGF-1R antibody currently advancing through Phase 1/2 clinical trials for thyroid eye disease (TED). The company's portfolio also features VRDN-002, an IGF-1R antibody undergoing Phase 1 clinical evaluation, alongside VRDN-003, a therapeutic antibody also designed to target IGF-1R for TED. Established in 2006, this Waltham, Massachusetts-based firm previously operated as Miragen Therapeutics, Inc., before changing its name to Viridian Therapeutics, Inc. in January 2021.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Viridian Therapeutics, Inc. (VRDN)
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Viridian Therapeutics, Inc. is a biotechnology firm committed to creating therapies for patients afflicted by serious illnesses. Its primary development efforts include VRDN-001, a humanized monoclonal anti-IGF-1R antibody currently advancing through Phase 1/2 clinical trials for thyroid eye disease (TED). The company's portfolio also features VRDN-002, an IGF-1R antibody undergoing Phase 1 clinical evaluation, alongside VRDN-003, a therapeutic antibody also designed to target IGF-1R for TED. Established in 2006, this Waltham, Massachusetts-based firm previously operated as Miragen Therapeutics, Inc., before changing its name to Viridian Therapeutics, Inc. in January 2021.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free